Aquestive Therapeutics Inc Revenue Growth Rates (AQST), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Aquestive Therapeutics Inc   (NASDAQ: AQST)
 

AQST's Revenue Growth by Quarter and Year

Aquestive Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AQST Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 13.82
1st Quarter March 14.45
FY 28.27

AQSTs Annual Revenue
Aquestive Therapeutics Inc 's Revenue in the fiscal year 2025 $ 44.55 millions
Aquestive Therapeutics Inc 's Revenue in the fiscal year 2024 $ 57.56 millions
Aquestive Therapeutics Inc 's Revenue in the fiscal year 2023 $ 50.58 millions
Aquestive Therapeutics Inc 's Revenue in the fiscal year 2022 $ 47.68 millions
Aquestive Therapeutics Inc 's Revenue in the fiscal year 2021 $ 50.83 millions




AQST Revenue second quarter 2026 Y/Y Growth Comment
Aquestive Therapeutics Inc achieved in the second quarter 2026, above Company average Revenue growth of 38.19% year on year, to $ 13.82 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 148 other companies have achieved higher Revenue growth. While Aquestive Therapeutics Inc ' s Revenue rise of 38.19% ranks overall at the positon no. 3343 in the second quarter 2026.


AQST Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 9.69 % -10.14 % 23.69 %
3rd Quarter September - -5.39 % 4.15 % 13.44 %
2nd Quarter June 38.19 % -50.25 % 51.81 % -0.23 %
1st Quarter March 65.71 % -27.63 % 8.27 % -9.29 %
FY   - -22.6 % 13.8 % -

Financial Statements
Aquestive Therapeutics Inc 's second quarter 2026 Revenue $ 13.82 millions AQST's Income Statement
Aquestive Therapeutics Inc 's second quarter 2025 Revenue $ 10.00 millions Quarterly AQST's Income Statement


AQST Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 1.64 % -12.33 % 1.62 %
3rd Quarter September - 28.1 % -32.64 % -1.81 %
2nd Quarter June -4.37 % 14.68 % 66.8 % 18.96 %
1st Quarter March 10.98 % -26.54 % -8.78 % 4.21 %
FY (Year on Year)   - -22.6 % 13.8 % -


Back to AQST Growth rate Comparisons >> Back to AQST Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #149
Healthcare Sector #452
Overall #3343

Revenue Y/Y Growth Statistics
High Average Low
25.45 % -3.4 % -29.76 %
(Jun 30 2024)   (Jun 30 2019)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #149
Healthcare Sector #452
Overall #3343
Revenue Y/Y Growth Statistics
High Average Low
25.45 % -3.4 % -29.76 %
(Jun 30 2024)   (Jun 30 2019)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Aquestive Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
147.29 % 7.69 % -61.89 %
(Jun 30 2020)  


AQST's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Aquestive Therapeutics Inc disclosed fall in Revenue from the first quarter by -4.37% to $ 13.82 millions, from $ 14.45 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 103 other companies have achieved higher Revenue quarter on quarter growth. While Aquestive Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 2400.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #104
Healthcare Sector #300
Overall #2400
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #104
Healthcare Sector #300
Overall #2400
Revenue Q/Q Growth Statistics
High Average Low
147.29 % 7.69 % -61.89 %
(Jun 30 2020)  


AQST's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Aquestive Therapeutics Inc disclosed fall in Revenue from the first quarter by -4.37% to $ 13.82 millions, from $ 14.45 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 103 other companies have achieved higher Revenue quarter on quarter growth. While Aquestive Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 2400.


Aquestive Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 54.09 $ 50.27 $ 44.55 $ 43.40 $ 44.13
Y / Y Revenue Growth (TTM) 22.56 % -7.3 % -22.61 % -26.32 % -24.38 %
Year on Year Revenue Growth Overall Ranking # 3415 # 1736 # 642 # 353 # 380
Seqeuential Revenue Change (TTM) 7.59 % 12.85 % 2.65 % -1.67 % -18.62 %
Seq. Revenue Growth (TTM) Overall Ranking # 3343 # 2591 # 1855 # 1513 # 773


Cumulative Revenue growth Comment
Aquestive Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 22.56% year on year, to $ 54 millions if the fiscal year would have ended in Jun 30 2026.
Aquestive Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average -3.4% and higher than -7.3% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 7.59 % from $50.27 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -3.4%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 7.59 % increase from $50.27 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 463 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1736 to 3415.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 149
Healthcare Sector # 464
Overall # 3415

Revenue TTM Y/Y Growth Statistics
High Average Low
25.45 %
 -3.4 %
-29.76 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 149
Sector # 452
S&P 500 # 3343
Cumulative Revenue growth Comment
Aquestive Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 22.56% year on year, to $ 54 millions if the fiscal year would have ended in Jun 30 2026.
Aquestive Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average -3.4% and higher than -7.3% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 7.59 % from $50.27 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -3.4%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 7.59 % increase from $50.27 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 463 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1736 to 3415.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 149
Healthcare Sector # 464
Overall # 3415

Revenue TTM Y/Y Growth Statistics
High Average Low
25.45 %
-3.4 %
-29.76 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 149
Sector # 452
S&P 500 # 3343




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AQST's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions
Guardant Health Inc 44.33%$ 44.332 millions
Omada Health Inc 43.27%$ 43.273 millions
Mannkind Corporation42.92%$ 42.922 millions
Butterfly Network Inc 42.47%$ 42.466 millions
Beta Bionics Inc 42.26%$ 42.261 millions
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions


About Aquestive Therapeutics Inc Revenue Growth Rates (AQST), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Aquestive Therapeutics Inc (CIK 1398733).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001398733-26-000042
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Aquestive Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.